Biotechnology

CRISPR-Cas9 is a precision gene-editing tool that uses a guide RNA to direct the Cas9 enzyme to a specific DNA sequence, where it creates a double-strand break. The cell's natural repair mechanisms then enable targeted modifications — corrections, insertions, or deletions. The first FDA-approved CRISPR therapy, Casgevy, treats sickle cell disease by editing BCL11A to restore fetal hemoglobin production.

AI accelerates drug discovery by predicting protein structures (AlphaFold 3), designing novel molecules from scratch (Chai-2 antibodies), identifying drug targets from genomic data, and optimizing clinical trial design. Over 200 AI-discovered drug candidates are in clinical trials as of 2026, with the first FDA approval expected by 2027–2028. The AI drug discovery market is projected to reach $28 billion by 2032.

Gene therapy introduces, removes, or modifies genetic material to treat disease — often using viral vectors (AAV) to deliver therapeutic genes. Cell therapy transfers living cells into a patient to treat disease — such as CAR-T cells engineered to target cancer. Genetically modified cell therapies (like CAR-T) combine both approaches. As of Q1 2025, 2,154 gene therapies and 966 non-genetically modified cell therapies are in development.

The global biotechnology market was valued at approximately $1.77 trillion in 2025 and is projected to grow at a CAGR of 13.6% through 2035, reaching $3.95 trillion by 2030. The US market is $316.41B, Europe $386.6B, and Asia Pacific $293.9B. The cell and gene therapy segment alone is projected to grow from $26.35B in 2025 to $146.31B by 2035.

Synthetic biology applies engineering principles to biology — designing and constructing new biological parts, devices, and systems. It includes programmable cells, bio-based materials, and AI-generated biological sequences. Tools like Evo 2 can generate viable synthetic viral genomes, while Chai-2 designs antibodies from scratch with 16% success rate — 100× better than traditional computational methods.

3D bioprinted tissues are already used for drug toxicity screening and disease modeling. Bioprinted tissue patches for cardiac repair are expected to enter clinical trials by 2029. Full lab-grown organs for transplantation remain further out, but decellularized organ scaffolds recellularized with patient cells are in early clinical testing. The tissue engineering market is projected to grow from $51.21B to $144.28B by 2030.

AlphaFold 3, developed by Google DeepMind and Isomorphic Labs, predicts the 3D structures of proteins, DNA, RNA, and small molecules — and crucially, how they interact. This goes beyond AlphaFold 2's protein-only predictions. AlphaFold 3 enables researchers to model drug-target interactions computationally, potentially saving years of lab work. Isomorphic Labs raised $600M and has $3B in pharma partnerships to develop AI-discovered drugs using AlphaFold 3.

Casgevy is the world's first FDA-approved CRISPR-Cas9 therapy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics. It treats sickle cell disease and beta-thalassemia by editing the BCL11A gene in patient stem cells to reactivate fetal hemoglobin production. The treatment involves collecting stem cells, editing them ex vivo, and reinfusing after myeloablative conditioning. It costs ~$2.2M per patient. As of 2026, over 100 patients have been treated with encouraging outcomes.